A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective, Including a 12-week Double-blind Extension Study and an Open-label 48 Week Extension Study

Trial Profile

A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective, Including a 12-week Double-blind Extension Study and an Open-label 48 Week Extension Study

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Canakinumab (Primary) ; Triamcinolone
  • Indications Gouty arthritis
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Acronyms Beta-RELIEVED
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Oct 2012 Last checked against ClinicalTrials.gov record (Parent trial: NCT01029652).
    • 25 Oct 2012 Last checked against ClinicalTrials.gov record (Parent trial: NCT01029652).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top